Reblozyl
Payments companies reported to CMS as associated with Reblozyl. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Reblozyl, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Reblozyl
These are the largest totals companies reported as associated with Reblozyl. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Leblanc | Durham, NC | Medical Oncology | $276,824.36 |
| Moshe Levy | Dallas, TX | Medical Oncology | $171,663.12 |
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $166,560.69 |
| Melhem Solh | Atlanta, GA | $154,623.66 | |
| Raji Shameem | Orlando, FL | Medical Oncology | $130,751.69 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $126,391.61 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $109,068.93 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $105,884.24 |
| Saeed Sadeghi | Santa Monica, CA | Hematology & Oncology | $95,234.93 |
| Mohit Narang | Owing Mills, MD | Medical Oncology | $84,836.19 |
Prescribed Reblozyl?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.